China’s Duality Biologics secures $90m in Series B led by Lilly Asia Ventures 2021-05-20T04:19:17-04:00May 20th, 2021| share this article! The round also attracted Huagai Capital, Oriza Holdings, YUNION Healthcare Fund, NRL Capital, and Green Pine Capital Partners Read More share this article! Related Posts Japan, EU universities to partner on fostering chip and AI talent May 3rd, 2024 Vietnam’s Galaxy Education eyes up to $20m fundraising to expand footprint May 3rd, 2024 Sony looks to boost film assets with $26bn Paramount acquisition May 3rd, 2024 Soundwill pushes to revalue Causeway Bay site as demand declines May 3rd, 2024
